m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression

m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression

Abstract Gefitinib has been widely applied for the treatment of lung adenocarcinoma (LUAD). However, the long-term application of gefitinib usually leads to acquired drug resistance in tumour patients, resulting in clinical treatment failure. Small nucleolar host gene 17 (SNHG17) has been shown to p...

Full description

Bibliographic Details
Main Authors: Heng Zhang, Shao-Qiang Wang, Li Wang, Hang Lin, Jie-Bo Zhu, Ri Chen, Lin-Feng Li, Yuan-Da Cheng, Chao-Jun Duan, Chun-Fang Zhang
Format: Article
Language:English
Published: Nature Publishing Group 2022-07-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-022-05050-x

Internet

https://doi.org/10.1038/s41419-022-05050-x

Similar Items